Subscribe To
ATAI / Why Atai Life Sciences Stock Stormed Higher This Week
ATAI News
By Proactive Investors
September 15, 2023
Psychedelics CEOs heartened by MDMA for PTSD study results as stocks maintain momentum
The success of a Phase 3 trial of MDMA for post-traumatic stress disorder (PTSD) which has put the therapy on track for U.S. Food and Drug Administrat more_horizontal
By GlobeNewsWire
September 14, 2023
atai Life Sciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
NEW YORK and BERLIN, Sept. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company ai more_horizontal
By GlobeNewsWire
September 6, 2023
atai Life Sciences to Participate in Upcoming September Investor Conferences
NEW YORK and BERLIN, Sept. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company ai more_horizontal
By Zacks Investment Research
September 6, 2023
atai Life Sciences N.V. (ATAI) Loses -15.43% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
atai Life Sciences N.V. (ATAI) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. more_horizontal
By Seeking Alpha
September 1, 2023
Atai Life Sciences: RL-007, Targeting Schizophrenia Subpopulation With No FDA Approved Therapies
Atai Life Sciences is advancing RL-007 for the treatment of cognitive impairment associated with schizophrenia, with top-line results expected in the more_horizontal
By Zacks Investment Research
August 21, 2023
Down -24.4% in 4 Weeks, Here's Why You Should You Buy the Dip in atai Life Sciences N.V. (ATAI)
atai Life Sciences N.V. (ATAI) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. more_horizontal
By Seeking Alpha
July 14, 2023
COMPASS: The Landscape Is Changing Quickly; Risk Is Up And Potential Down
COMPASS: The Landscape Is Changing Quickly; Risk Is Up And Potential Down more_horizontal
By Market Watch
June 23, 2023
FDA issues guidance on psychedelic drug clinical trials
The U.S. Food and Drug Administration on Friday issued its first draft guidance on psychedelic drug clinical trials, outlining considerations for comp more_horizontal